TSMHT
HAE icon

Thurston Springer Miller Herd & Titak’s Haemonetics HAE Stock Holding History

Thurston Springer Miller Herd & Titak’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-99
Closed -$7.39K – 893
2025
Q2 		$7.39K Hold
99
– – ﹤0.01% 1208
2025
Q1 		$6.29K Sell
99
-12
-11% -$816 ﹤0.01% 1226
2024
Q4 		$8.67K Hold
111
– – ﹤0.01% 921
2024
Q3 		$8.92K Buy
+111
New +$8.97K ﹤0.01% 1082

Other funds holding HAE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RRAM
River Road Asset Management Louisville, Kentucky $8.99B AUM 12.83% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Thurston Springer Miller Herd & Titak's HAE Position: Q3 2025 in Review

Thurston Springer Miller Herd & Titak sold out of Haemonetics (HAE) in Q3 2025, closing a stake of 99 shares — an estimated $7.39K sold.

Thurston Springer Miller Herd & Titak first reported a position in HAE in Q3 2024 and held it in 4 quarters. The position peaked at $8.92K in Q3 2024. 301 funds tracked by Wall St. Rank hold HAE as of Q3 2025.

  • Thurston Springer Miller Herd & Titak reported no remaining Haemonetics position as of Q3 2025 after selling out during the quarter.
  • Thurston Springer Miller Herd & Titak sold 99 Haemonetics shares in Q3 2025, an estimated $7.39K.
  • Thurston Springer Miller Herd & Titak first reported a position in Haemonetics in Q3 2024 and held it in 4 quarters.
  • Thurston Springer Miller Herd & Titak's Haemonetics position peaked at $8.92K in Q3 2024.
  • 301 funds tracked by Wall St. Rank held Haemonetics as of Q3 2025.

Based on Thurston Springer Miller Herd & Titak's 13F filing for Q3 2025, filed 7 Oct 2025.